TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01523431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Injection [Camptosar]
Description: CPT-11 will be administered according to UGT1A1 genotypes. Patients with UGT1A1 \*1/\*1 or heterozygous UGT1A1\*1/\*28 or \*1/\*6 will receive standard dose of CPT-11. Patients with homozygous UGT1A1\*28/\*28, \*6/\*6 or \*28/\*6, will be randomized in a 1:1 ratio to receive standard dose of CPT-11 or 50% reduced dose of CPT-11.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Injection [Camptosar]
Description: CPT-11 will be administered according to UGT1A1 genotypes. Patients with UGT1A1 \*1/\*1 or heterozygous UGT1A1\*1/\*28 or \*1/\*6 will receive standard dose of CPT-11. Patients with homozygous UGT1A1\*28/\*28, \*6/\*6 or \*28/\*6, will be randomized in a 1:1 ratio to receive standard dose of CPT-11 or 50% reduced dose of CPT-11.
Study: NCT03279510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hearing aids
Description: Subjects are fit with hearing aids.
Study: NCT01523431

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Injection [Camptosar]
Description: CPT-11 will be administered according to UGT1A1 genotypes. Patients with UGT1A1 \*1/\*1 or heterozygous UGT1A1\*1/\*28 or \*1/\*6 will receive standard dose of CPT-11. Patients with homozygous UGT1A1\*28/\*28, \*6/\*6 or \*28/\*6, will be randomized in a 1:1 ratio to receive standard dose of CPT-11 or 50% reduced dose of CPT-11.
Study: NCT00894530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin ophthalmic solution, 1%
Description: One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days
Study: NCT01523431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: The 5-FU dosage will remain the standard.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: The 5-FU dosage will remain the standard.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: The 5-FU dosage will remain the standard.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: The LV dosage will remain the standard.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: The LV dosage will remain the standard.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: The LV dosage will remain the standard.
Study: NCT02042144

Intervention type: DRUG
Intervention: Stivarga (Regorafenib, BAY73-4506)
Description: Patients diagnosed with mCRC who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom the decision has been made per investigator's routine treatment practice to prescribe regorafenib
Study: NCT04003389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fezolinetant
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fezolinetant
Description: administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: administered orally
Study: NCT03586453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Patients who fulfill eligibility criteria will be entered into the trial to receive Osimertinib.~After the screening procedures confirm participation in the research study:~* Osimertinib: Oral, Daily 28 day cycle.~* Radiographic assessment: every 2 cycles for first 6 months and then every 3 cycles until disease progression.~* Tumor biopsy between C4 and C8 and at disease progression
Study: NCT04130867

Intervention type: PROCEDURE
Intervention: pHRM
Description: Pharyngeal high--resolution manometry (pHRM) provides direct and objective measurement of pressure changes in the pharynx that characterize basic mechanisms of swallowing.

Intervention type: PROCEDURE
Intervention: pHRM
Description: Pharyngeal high--resolution manometry (pHRM) provides direct and objective measurement of pressure changes in the pharynx that characterize basic mechanisms of swallowing.

Intervention type: PROCEDURE
Intervention: pHRM
Description: Pharyngeal high--resolution manometry (pHRM) provides direct and objective measurement of pressure changes in the pharynx that characterize basic mechanisms of swallowing.

Intervention type: PROCEDURE
Intervention: VFSS
Description: Videofluoroscopic Swallow Study (VFSS) enables real-time visualization of bolus flow during swallow movement.
Study: NCT03228251

Intervention type: OTHER
Intervention: Stroke team simulation training
Description: The participating centers identify 3-4 senior staff of different professional backgrounds (e.g. senior neurologist, neurointerventionalist, head nurse) who will design a stroke team algorithm tailored to the local circumstances of the stroke center. The centers will be invited to a joint train-the-trainer seminar at the sponsor's institution where they present their algorithm to the participants of all seven stroke centers for discussion to invite suggestions for streamlining and improvement. The teams will be introduced to the concept of simulation-based stroke team training. After the seminar, the principal investigator and the stroke team trainer will visit all centers for one on-site stroke team training and provide teaching materials. Afterwards, each center will be invited to schedule two additional stroke team trainings with the stroke team trainer that will be led by e.g. the senior neurologist from the stroke unit with use of a simulation manikin.
Study: NCT00517686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information feedback intervention
Description: This study will evaluate an information feedback intervention: measuring, reporting and feeding back information to primary care teams on the need for treatment intensification in patients at high risk for cardiovascular disease (CVD).
Study: NCT00707018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External rotation shoulder sling
Description: The external rotation sling will be adjusted to position the injured upper extremity in 90 degrees of elbow flexion, 0 degrees of shoulder abduction and flexion, and 10 to 15 degrees of external rotation at the shoulder.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Internal rotation shoulder sling
Description: The internal rotation sling will be adjusted to position the injured upper extremity in 90 degrees of elbow flexion, 0 degrees of shoulder abduction and flexion, and 70 to 80 degrees of internal rotation at the shoulder.
Study: NCT04130867

Intervention type: PROCEDURE
Intervention: VFSS
Description: Videofluoroscopic Swallow Study (VFSS) enables real-time visualization of bolus flow during swallow movement.

Intervention type: PROCEDURE
Intervention: VFSS
Description: Videofluoroscopic Swallow Study (VFSS) enables real-time visualization of bolus flow during swallow movement.
Study: NCT01340118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: once daily inhalation with 400 µg budesonide (dry powder)during 6 weeks
Study: NCT04331769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuCinch Ventricular Restoration System
Description: AccuCinch Ventricular Restoration System

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guideline-Directed Medical Therapy
Description: Guideline-Directed Medical Therapy
Study: NCT03429907

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Exercises
Description: Participants do daily mind-body exercises for 14 days before starting chemotherapy. The exercises are about 10 minutes per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy.
Study: NCT02295098

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural catheter placement
Description: Thoracic epidurals work by delivering local anesthetics and narcotics to the epidural space, which then diffuse into the spinal nerve roots and block the transmission of pain from the chest wall to the spinal cord and brain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paracostal catheter placement
Description: Paracostal catheters run along the outer surface of the chest wall and act by delivering local anesthetics to the intercostal nerves as traverse the lower border of the ribs.
Study: NCT05308485

Intervention type: OTHER
Intervention: Events exposure questionnaire
Description: Events exposure questionnaire that assess the occurrence of exposure to events and their severity over a limited period

Intervention type: OTHER
Intervention: Events exposure questionnaire
Description: Events exposure questionnaire that assess the occurrence of exposure to events and their severity over a limited period

Intervention type: OTHER
Intervention: Events exposure questionnaire
Description: Events exposure questionnaire that assess the occurrence of exposure to events and their severity over a limited period
Study: NCT01562015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib
Description: Ganetespib 200 mg/m2 administered 1 time per week for the first three weeks of a four week treatment cycle (Days 1, 8, and 15 of the 28 Day treatment cycle).
Study: NCT00005398

Intervention type: OTHER
Intervention: There is no intervention
Description: No applicable
Study: NCT01534832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innervision Surgical Smoke Removal System
Description: Smoke removal by electrostatic precipitation
Study: NCT01466725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT03321929

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LUM Imaging System
Description: Drug: LUM015 Device: LUM 2.6 Imaging Device
Study: NCT03576677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: Levosimendan, 2.5 mg/mL concentrate for dilution. 5 mL of the study drug will be injected into a 245 mL isotonic glucose solution.~Patients will receive a 6 hours infusion of this study drug at an infusion rate of 0.2 µg/kg/min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo solution will be prepared by adding 10 mL of 5% dextrose to a vial containing Soluvit (vitamin B) under aseptical conditions. 5 mL of this solution is then added to 245 mL of isotonic sodium chloride solution.~5% dextrose and vitamin B are added to ensure yellow coloring indistinguishable from the active drug (levosimendan).~Patients will receive a 6 hours infusion of this study drug. Infusion rate will be calculated in similar fashion to the levosimendan group.
Study: NCT03311685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vaginal tactile imager
Description: Patients will undergo elasticity assessment with vaginal tactile imaging the be once before surgical repair and twice after surgery in a 3 month interval.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vaginal tactile imager
Description: Patients will undergo elasticity assessment with vaginal tactile imaging the be once before surgical repair and twice after surgery in a 3 month interval.
Study: NCT03766997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Betamethasone Injection
Description: local injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Butyrate 0.1% Cream
Description: topical use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone Butyrate 0.1% Cream
Description: topical use
Study: NCT03947879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-glutamine
Description: 15 g of L-glutamine twice daily by mouth for 3 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No L-glutamine
Description: The same patients will be given no L-glutamine for 3 months.
Study: NCT02714205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transdermal nitroglycerin
Description: Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
Study: NCT00062738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine
Description: Paroxetine CR 12.5 - 25 mg q hs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Description: nortriptyline 25 - 75 mg q hs

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study: NCT02277210

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flushing
Description: aspiration of follicles that are larger than 10 mm on both sides followed by follicular flushing for up to 4 times. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Flushing
Description: aspiration of follicles that are larger than 10 mm on both sides followed by follicular flushing for up to 4 times. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
Study: NCT04263922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaiqihuang granules
Description: Huaiqihuang granules, 2 bags at a time, 3 times a day. Valsartan capsule simulant, 80mg at a time, once a day. Oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan capsule
Description: Valsartan capsule, 80mg at a time, once a day. Huaiqihuang granules simulant, 2 bags at a time, 3 times a day. Oral administration.
Study: NCT01842464

Intervention type: PROCEDURE
Intervention: Anterior Sacro-Spinous
Description: Anterior Sacro-Spinous
Study: NCT04222725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRS01 eye drops
Description: Dosed 4 times a day (QID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRS01 eye drops
Description: Dosed QID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRS01 eye drops
Description: Dosed QID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo eye drops
Description: Dosed QID
Study: NCT02947139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of DWC20155/DWC20156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of DWC20155/DWC20156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC20161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC20161
Study: NCT05286398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palatoplasty
Description: Surgical closure of palatal defect

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palatoplasty
Description: Surgical closure of palatal defect

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Addition silicone impression
Description: diagnostic impression for maxillary arch

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Addition silicone impression
Description: diagnostic impression for maxillary arch

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Addition silicone impression
Description: diagnostic impression for maxillary arch
Study: NCT01507545

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MORAb-004
Description: MORAb-004 8mg per kg IV once a week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - normal saline IV once a week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best supportive care
Description: Best supportive care to improve quality of life

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best supportive care
Description: Best supportive care to improve quality of life
Study: NCT02035072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 100 mg/m2

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated RT
Description: Hypofractionated radiotherapy (35 Gy in 7 fractions)
Study: NCT04042311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: a high-intensity interval training programme completed 3 times a week for 6 weeks using a stationary Wattbike.
Study: NCT02725606

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Recombinant Human G-CSF
Description: subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GW003
Description: subcutaneous
Study: NCT02065440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhinoebastel
Description: Rhinoebastel(ebastine 10mg/pseudoephedrine 120mg) 1 cap/day for 1 week unless progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 cap/day for 1 week unless progression or unacceptable toxicity develops
Study: NCT02251730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Description: Refer for smoking cessation
Study: NCT03726216

Intervention type: DRUG
Intervention: Xydalba
Description: Information will be recorded about Xydalba administration (e.g. dose(s), number of infusions, length of infusions, dates or schedule of administration, sites of administration \[e.g. hospital, ICU\]), and reason for discontinuation, including response to treatment to assess whether the patient was clinically improving when Xydalba was discontinued
Study: NCT02179307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week progressive strength training protocol
Description: Every study participant will complete 12 weeks of progressive strength training with one leg performing 1-set per exercise per session and the contralateral leg performing 3-sets per exercise per session. Allocation of dominant/non-dominant leg to either 1- or 3-set protocol will be done in a stratified, randomized fashion (stratified with regard to sex and baseline strength).
Study: NCT04534062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF D2 technique
Description: PNF D2 technique of bilateral upper limb will be performed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF D2 technique
Description: PNF D2 technique of bilateral upper limb will be performed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF D2 technique
Description: PNF D2 technique of bilateral upper limb will be performed
Study: NCT03562221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten free diet
Description: Controlled gluten free diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules
Study: NCT02604017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Tablet; ABT-493 coformulated with ABT-530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Tablet; ABT-493 coformulated with ABT-530
Study: NCT02477423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin
Description: Ampicillin will be given as routine antibiotic coverage for those in the active arm, as the standard initial antibiotic used within the neonatal unit. It may also be used for patients who are not eligible for randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicins
Description: Gentamicin will be given as routine antibiotic coverage for those in the active arm, as the standard initial antibiotic used within the neonatal unit. It may also be used for patients who are not eligible for randomization.
Study: NCT02725606

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GW003
Description: subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GW003
Description: subcutaneous
Study: NCT01505426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: oral, concomitant use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: oral, concomitant use
Study: NCT02477423

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline will be given as placebo for those in the placebo comparator group.
Study: NCT02882074

Intervention type: DRUG
Group type: OTHER
Intervention: Human albumin
Description: human albumin 5% during surgery

Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxyethyl starch
Description: 6% Hydroxyethyl starch 130/0.4 during surgery
Study: NCT01505426

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral